The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH

Neurogastroenterology and Motility

Volumn 24, Issue 5, 2012, Pages 426-431

  Chowers, Y ^a   Atarot, T ^a   Pratha, V S ^b   Fass, R ^c  

^a Vecta Ltd   (Israel)

^b Clinical Applications Laboratories   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Gastroesophageal reflux disease; Nighttime gastric acid reflux; Nighttime heartburn; Omeprazole; Succinic acid

Indexed keywords

OMEPRAZOLE; SUCCINIC ACID; UNCLASSIFIED DRUG; VECAM;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENTERIC COATED TABLET; FEMALE; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; STOMACH PH; THERAPY EFFECT;

ADULT; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DRUG COMBINATIONS; EATING; ENDPOINT DETERMINATION; ESOPHAGEAL SPHINCTER, LOWER; FEMALE; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OMEPRAZOLE; PROTON PUMP INHIBITORS; SUCCINIC ACID; YOUNG ADULT;

EID: 84859701753     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2012.01884.x     Document Type: Article

References (20)

1. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
2. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 1487-93.
3. Farup C, Kleinman L, Sloan S et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161: 45-52.
4. Dickman R, Parthasarathy S, Malagon IB et al. Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther 2007; 26: 41-8.
5. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473-7.
6. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000; 14: 709-14.
7. Chowers Y, Atarot T, Kostadinov A et al. PPI activity is optimized by VB101, a parietal cell activator. Gastroenterology 2008; 134: A172.
8. Prichard PJ, Yeomans ND, Mihaly GW et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88: 64-9.
9. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 1267-72.
10. Thomson AB, Cohen P, Ficheux H et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther 2006; 23: 1179-87.
11. Lagergren J, Bergström R, Linfgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
12. Fass R. Night time GERD: an under appreciated condition challenges in the diagnosis and management of supreasophageal complications of GERD (Shaker, R.) Update on Treatment Options for Nighttime GERD (Neudeck, B.). University of Michigan Medical School. Available at: (Online). 2008:1.
13. Fass R. Risk factors for nighttime gastroesophageal reflux disease. Medscape Gastroenterol 2006; 8: 1-4.
14. Orr W. Sleep and gastroesophageal reflux. Medscape Gastroenterol 2005; 7: 1-3.
15. Orr W. Consequences of nighttime heartburn - quality of life and sleep. Medscape Gastroenterol 2006; 8: 1-3.
16. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
17. Katz PO. Lessons learned from intragastric pH monitoring. J Clin Gastroenterol 2001; 33: 107-13.
18. Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004; 19: 1105-10.
19. Chowers Y, Atarot T, Kostadinov A et al. PPI activity is optimized by VB101, a parietal cell activator. Gastroenterology 2008; 134(4 Suppl. 1).
20. Katz PO, Koch FK, Ballard ED et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther 2007; 25: 197-205.